STOCK TITAN
  1. Home
  2. Sec-filings
  3. IBRX
  4. [Form 4] ImmunityBio, Inc. Insider Trading Activity

ImmunityBio (IBRX) director trades 131K shares, exercises 55,979 options

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ImmunityBio, Inc. director Cheryl Cohen reported an exercise-and-sale transaction involving the company’s common stock. On 2026-07-02, she sold 131,210 shares in an open‑market transaction at a weighted average price of $9.5034 per share, under a pre‑arranged Rule 10b5-1 trading plan.

On the same date, Cohen exercised stock options to acquire 55,979 common shares at an exercise price of $2.98 per share, reducing her option position while increasing her direct shareholdings before the sale. Following these transactions, she directly holds 125,386 common shares and 111,958 stock options.

Positive

  • None.

Negative

  • None.
Insider Cohen Cheryl
Role null
Sold 131,210 shs ($1.25M)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 55,979 $0.00 --
Exercise Common Stock 55,979 $2.98 $167K
Sale Common Stock 131,210 $9.5034 $1.25M
Holdings After Transaction: Stock Option (right to buy) — 111,958 shares (Direct, null); Common Stock — 256,596 shares (Direct, null)
Footnotes (1)
  1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026. Represents the weighted average share price of an aggregate total of 131,210 shares sold in the price range of $9.50 to $9.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Shares sold 131,210 shares Open-market sale of common stock on July 2, 2026
Sale price $9.5034 per share Weighted average sale price, trades between $9.50 and $9.52
Options exercised 55,979 shares Common stock acquired via option exercise on July 2, 2026
Option exercise price $2.98 per share Stock option (right to buy) exercise price
Shares held after 125,386 shares Direct ImmunityBio common stock holding after transactions
Remaining options 111,958 options Stock options outstanding after exercise, expiring June 14, 2032
10b5-1 plan date February 27, 2026 Date Rule 10b5-1 trading plan was entered into
Rule 10b5-1 trading plan regulatory
"The sale of shares reported ... was effected pursuant to a Rule 10b5-1 trading plan entered into..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy) financial
""security_title": "Stock Option (right to buy)""
weighted average share price financial
"Represents the weighted average share price of an aggregate total of 131,210 shares sold..."
derivative exercise/conversion financial
""transaction_action": "derivative exercise/conversion""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did ImmunityBio (IBRX) director Cheryl Cohen report?
Cheryl Cohen reported an exercise-and-sale transaction. She exercised options for 55,979 ImmunityBio shares at $2.98, then sold 131,210 shares in open-market trades at a weighted average price of $9.5034, all on July 2, 2026, under a Rule 10b5-1 plan.

How many ImmunityBio (IBRX) shares did Cheryl Cohen sell and at what price?
Cohen sold 131,210 ImmunityBio common shares. The weighted average sale price was $9.5034 per share, with individual trades executed in a narrow range between $9.50 and $9.52, as disclosed, all occurring on July 2, 2026.

Were Cheryl Cohen’s ImmunityBio (IBRX) stock sales pre-planned?
Yes. The filing states the 131,210-share sale was executed under a Rule 10b5-1 trading plan entered into on February 27, 2026. Such plans schedule trades in advance, indicating the timing of sales was pre-arranged rather than a spontaneous market decision.

What stock options did Cheryl Cohen exercise for ImmunityBio (IBRX)?
Cohen exercised stock options covering 55,979 ImmunityBio shares at an exercise price of $2.98 per share. These options, originally exercisable from June 12, 2023 and expiring June 14, 2032, converted into common stock as part of her July 2, 2026 transactions.

How many ImmunityBio (IBRX) shares does Cheryl Cohen hold after these transactions?
After the July 2, 2026 transactions, Cohen directly holds 125,386 ImmunityBio common shares. She also retains 111,958 stock options, providing additional potential future equity exposure if exercised before their stated expiration date of June 14, 2032.

What is the nature of Cheryl Cohen’s remaining ImmunityBio (IBRX) option position?
Following the option exercise, Cohen holds 111,958 remaining stock options, each with a $2.98 exercise price and a June 14, 2032 expiration. These options represent rights to buy additional ImmunityBio shares, potentially expanding her equity stake if she chooses to exercise them later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cohen Cheryl
(Last)(First)(Middle)
C/O IMMUNITYBIO, INC.
3530 JOHN HOPKINS COURT
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/02/2026M55,979A$2.98256,596D
Common Stock07/02/2026S(1)131,210D$9.5034(2)125,386D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.9807/02/2026M55,97906/12/202306/14/2032Common Stock55,979$0111,958D
Explanation of Responses:
1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.
2. Represents the weighted average share price of an aggregate total of 131,210 shares sold in the price range of $9.50 to $9.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Remarks:
/s/ Philip LoScalzo, as Attorney-in-Fact07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR